Collectively, these results demonstrate that early senolytic targeting of MCL-1+ senescent TEC using UMI-77 effectively attenuates tubular injury and interstitial fibrosis in the AAN model, while delayed intervention offers limited therapeutic benefit. This evidence concerns the gene MCL1 and Balkan nephropathy.